Study of Erenumab (AMG 334) in Women With Hot Flashes

Overview

The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.

Full Title of Study: “Randomized, Stratified, Parallel-group, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 334 in Women With Hot Flashes Associated With Menopause”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 11, 2014

Detailed Description

This study will test the hypothesis that the vasodilation associated with capsaicin-induced dermal blood flow (DBF) provides a good model for the vasodilation associated with hot flashes; therefore erenumab doses that cause DBF inhibition will be safe and well tolerated, and will be effective in the reduction of the frequency and/or severity of HFs.

Interventions

  • Biological: Erenumab
    • Administered via subcutaneous injection.
  • Drug: Placebo
    • Administered via subcutaneous injection

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo
    • Participants received a single dose of placebo administered by subcutaneous injection.
  • Experimental: Erenumab
    • Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.

Clinical Trial Outcome Measures

Primary Measures

  • Ratio of Week 4 to Baseline Average Number of Daily Moderate to Severe Hot Flashes
    • Time Frame: Baseline (days -7 to day 1 predose) and week 4 (days 21 to 27)
    • The severity of hot flashes was assessed by participants based on the following categories: Mild: sensation of heat without sweating, mild flushing; Moderate: sensation of heat, face flushed, slightly clammy, some sweating, able to continue activity, may want to remove layers of clothing or covers at night; Severe: sensation of heat with more severe sweating, have to stop current activity, may have to change clothing. Baseline (BL) number of hot flashes is the average number of moderate or severe hot flashes per 24 hours from day -7 to day 1 predose based on geometric mean, and the week 4 number of hot flashes is the average number of moderate or severe hot flashes per 24 hours from day 21 to day 27 based on geometric mean. The ratio of week 4 to BL was used to assess change from BL to week 4 via a log transformation (log[week4/BL] = log[week4] – log[BL]), which was estimated using a repeated measures analysis. The ratio was obtained via an exponential back-transformation.

Secondary Measures

  • Ratio of Week 4 to Baseline Daily Hot Flash Severity Score
    • Time Frame: Baseline (days -7 to day 1 predose) and week 4 (days 21 to 27)
    • The daily severity score was calculated according to the following: (Number of mild hot flashes * 1) + (number of moderate hot flashes * 2) + (number of severe hot flashes * 3). The baseline daily hot flash severity score is the geometric mean daily hot flash severity score from day -7 to day 1 predose, and the week 4 daily hot flash severity score is the geometric mean daily hot flash severity score from day 21 to day 27. The ratio of week 4 to baseline (week 4 / baseline) was used to assess change from baseline to week 4 via a log transformation (log[week4/BL] = log[week4] – log[baseline]), which was estimated using a repeated measures analysis. The ratio was obtained via an exponential back-transformation.
  • Number of Participants With Treatment-emergent Adverse Events
    • Time Frame: 16 weeks
    • A treatment-emergent adverse event is any adverse event that began or worsened after the initial dose of study drug and before the end of study. A serious adverse event is an adverse event that met at least 1 of the following serious criteria: fatal life threatening required inpatient hospitalization or prolongation of existing hospitalization resulted in persistent or significant disability/incapacity congenital anomaly/birth defect. other medically important serious event A treatment-related adverse event (TRAE) is any treatment-emergent adverse event that per investigator review had a reasonable possibility of being caused by the study drug.
  • Maximum Observed Concentration (Cmax) of Erenumab After a Single Dose
    • Time Frame: Predose and 4 hours, 2, 3, 4, 8, 12, 15, 22, 29, 43, 50, 57, 64, 78, 85, and 113 days post-dose
    • Blood samples were analyzed using an enzyme-linked immunosorbent assay (ELISA) following a validated analytical procedure.
  • Time to Maximum Observed Concentration (Tmax) of Erunumab After a Single Dose
    • Time Frame: Predose and 4 hours, 2, 3, 4, 8, 12, 15, 22, 29, 43, 50, 57, 64, 78, 85, and 113 days post-dose
  • Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) for Erenumab
    • Time Frame: Predose and 4 hours, 2, 3, 4, 8, 12, 15, 22, 29, 43, 50, 57, 64, 78, 85, and 113 days post-dose
  • Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for Erenumab
    • Time Frame: Predose and 4 hours, 2, 3, 4, 8, 12, 15, 22, 29, 43, 50, 57, 64, 78, 85, and 113 days post-dose
  • Terminal Half-life (T1/2) of Erenumab
    • Time Frame: Predose and 4 hours, 2, 3, 4, 8, 12, 15, 22, 29, 43, 50, 57, 64, 78, 85, and 113 days post-dose
  • Number of Participants With Treatment-emergent Suicidal Ideation
    • Time Frame: 16 weeks
    • The Columbia Suicide Severity Rating Scale (C-SSRS) was used to assess suicidal ideation during the study based on the following Yes/No questions: Have you wished you were dead or wished you could go to sleep and not wake up? Have you actually had any thoughts of killing yourself?
  • Number of Participants Who Developed Anti-erenumab Antibodies After a Single Dose
    • Time Frame: 16 weeks
    • Two validated assays were used to detect the presence of anti-erenumab antibodies. First, an electrochemiluminescent (ECL) bridging immunoassay was used to detect antibodies capable of binding erenumab. Second, a cell based bioassay was used to test positive binding antibody samples for neutralizing activity against erenumab. A participant was defined as positive for developing anti-erenumab antibodies if they were binding antibody positive postbaseline with a negative or no result at baseline. If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.

Participating in This Clinical Trial

Inclusion Criteria

  • female subjects with hot flashes associated with menopause between 45 and 65 years of age, inclusive, with no history or evidence of clinically relevant medical disorders as determined by the investigator in consultation with the Amgen physician. Exclusion Criteria:

  • History or evidence of clinically significant disorder (including psychiatric), condition or disease that, in the opinion of the Investigator or Amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

Gender Eligibility: Female

Minimum Age: 45 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Amgen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • MD, Study Director, Amgen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.